Insider Buying: Polaryx Therapeutics (NASDAQ:PLYX) CEO Purchases 88,453 Shares of Stock

Posted by on May 28th, 2026

Polaryx Therapeutics, Inc. (NASDAQ:PLYX – Get Free Report) CEO Alex Keun Mo Yang purchased 88,453 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was bought at an average price of $4.07 per share, for a total transaction of $360,003.71. Following the completion of the acquisition, the chief executive officer owned 24,233,249 shares of the company’s stock, valued at approximately $98,629,323.43. The trade was a 0.37% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Polaryx Therapeutics Trading Up 21.5%

Shares of NASDAQ PLYX traded up $0.54 during mid-day trading on Thursday, reaching $3.05. The company had a trading volume of 853,993 shares, compared to its average volume of 1,495,093. The stock’s 50-day moving average price is $5.06. Polaryx Therapeutics, Inc. has a 52 week low of $2.07 and a 52 week high of $48.91.

Polaryx Therapeutics (NASDAQ:PLYX – Get Free Report) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.03) EPS for the quarter.

Analysts Set New Price Targets

Several research firms have recently commented on PLYX. Maxim Group began coverage on shares of Polaryx Therapeutics in a report on Friday, February 27th. They issued a “buy” rating and a $10.00 price target for the company. Weiss Ratings began coverage on shares of Polaryx Therapeutics in a report on Friday, April 24th. They issued a “sell (e-)” rating for the company. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.00.

Read Our Latest Stock Analysis on PLYX

Polaryx Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

Featured Stories

Receive News & Ratings for Polaryx Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polaryx Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.